Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of color with psoriasis are 70% less likely to be prescribed a biologic than ...
Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...